Clever Culture Systems Limited · ASX:CC5
Clever Culture Systems — Shareholder Meeting (November 2026)
7 slides from Clever Culture Systems's shareholder meeting presentation, Nov 17, 2026
Slide 1: Managing Director's Presentation – 2026 AGM
Clever Culture Systems Ltd 16 Anster St Adelaide SA 5000 www.cleverculturesystems.com ASX:CC5 For personal use only MANAGING DIRECTOR’S PRESENTATION – 2026 AGM Adelaide, Australia, 17 November 2026: Leaders in AI microbiology automation, Clever Culture Systems Ltd (ASX: CC5) is pleased to provide th
Slide 2: CEO Presentation: AI-powered microbiology
CEO Presentation AI-powered microbiology personal use only Revolutionising microbial quality control in pharmaceutical manufacturing Annual General Meeting 17 November 2026 Clever Culture Systems ASX: CC5 1
Slide 3: Commercial traction
Commercial traction H1 FY27 progressing as a step-change in sales performance personal use only COMPLETED H1 FY 2 7 S A LE S A ND N EW EV A L UA TI ON S 3 Sales completed and invoiced in Q1 FY27 to Novo and AstraZeneca APAS® instruments 2 Purchase orders received from existing global pharma customer
Slide 4: APAS Revolution: Substantial growth opportunity unlocked
APAS® Revolution Substantial growth opportunity unlocked personal use only Built on proven APAS® technology, funded and launching H1 CY2028 $4.3B ~50% 3,400 <2 yrs revised increased TAM uplift to APAS® TAM instrument opportunity payback after launch TIMELINE Nov 2026 Next CY2027 CY2028 Within 2 year
Slide 5: Expanded opportunity
Expanded opportunity Targeting a 5,700 APAS® instrument TAM: $4.3B personal use only APAS® platforms to address the entire market opportunity APAS® Revolution APAS® Independence 3,400 instrument opportunity / $1.5B 2,300 instrument opportunity / $2.8B 30% 25% 20% 15% 10% 5% 25% 25% 25% 15% 10% 0% <1
Slide 6: Same revenue model
Same revenue model One revenue model across both APAS instruments personal use only Independence and Revolution share a broadly equivalent revenue split1 Product / Approx. Description Revenue Model Service Split APAS® Upfront Capex APAS® Independence (inc. financing 40% Instruments and APAS® Revoluti
Slide 7: Growth outlook
Growth outlook TODAY NEXT personal use only Today: APAS® proven and Scale: building on that building trust with global success to increase global pharma market opportunity 37 instruments 9 top-20 pharma GMP use routinely Second product, Recurring revenue Broad based installed customers by customers
Clever Culture Systems — Shareholder Meeting (November 2026) on 6ix